César Ramos-Remus

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Josef S Smolen, André Beaulieu, Andrea Rubbert‐Roth et al. · The Lancet · 2008 · 1.4K citations

Inflammation, Rheumatology, Rheumatoid Disorder +10

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 612 citations · Full text

Autoimmune Disease, Systemic Scleroderma, Immunology +3

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

K. Visser, Wanruchada Katchamart, Estíbaliz Loza et al. · Annals of the Rheumatic Diseases · 2008 · 485 citations · Full text

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

Roy Fleischmann, Michael Schiff, Désirée van der Heijde et al. · Arthritis & Rheumatology · 2016 · 396 citations · Full text

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14